For type 2 diabetes mellitus. ANDA 77880, held by Amneal Pharms Ny. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 77880 (Metformin Hydrochloride), held by Amneal Pharms Ny, was first approved by FDA on Jun 5, 2006, with 6 approved supplements and 0 published complete response letters.
Metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 5, 2006 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Discontinued |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Discontinued |
| Aug 11, 2026 | Supplement 32Labeling · Standard review | Approved | None posted |
| Jul 23, 2026 | Supplement 29Labeling · Standard review | Approved | None posted |
| Aug 27, 2019 | Supplement 21Labeling · Standard review | Approved | None posted |
| Aug 27, 2019 | Supplement 22Labeling · Standard review | Approved | None posted |
| Mar 20, 2008 | Supplement 2Manufacturing | Approved | None posted |
| Feb 15, 2007 | Supplement 1Labeling | Approved | None posted |
| Jun 5, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters